晚期肺鳞癌一线吉西他滨/紫杉醇与铂类二联方案疗效比较  

Comparison of the clinical efficacy of gemcitabine/ paclitaxel platinum doublets in chemotherapy of advanced squamous lung cancer

作　　者：赵玲娣[1,2] 李威[1,2] 张勇[1,2] 王子兵[1,2] 高全立[1,2] 

机构地区：[1]郑州大学附属肿瘤医院 [2]河南省肿瘤医院,河南郑州450008

出　　处：《现代肿瘤医学》2015年第8期1078-1080,共3页Journal of Modern Oncology

摘　　要：目的:比较晚期肺鳞癌患者一线吉西他滨/紫杉醇与铂类二联方案的临床疗效,为晚期肺鳞癌患者个体化化疗方案筛选提供临床依据。方法:回顾性分析2008年6月至2012年5月经病理确诊的、一线应用吉西他滨或紫杉醇铂二联方案化疗的转移性肺鳞癌患者62例,分为2个治疗组,每组患者均为31例。结果:吉西他滨铂二联方案客观有效率为32.3%,紫杉醇铂二联方案客观有效率为35.5%,二者比较差异不具有统计学意义(P=0.737);两组患者中位无进展生存期分别为5个月(95%CI 3.2-6.8个月)和5个月(95%CI 3.7-6.3个月),二者比较差异不具有统计学意义(P=0.058);两组患者中位生存期分别为10个月(95%CI8.9-11.1个月)和12个月(95%CI 9.7-14.3个月),二者比较差异不具有统计学意义(P=0.087)。结论:在晚期肺鳞癌中,吉西他滨/紫杉醇铂二联方案的疗效相似,其中紫杉醇铂二联具有生存优势。Objective： We compared the clinical efficacy of gemcitabine/paclitaxel combined platinum in metastat- ic lung squamous cancer. Methods： We analysed retrospectively 62 cases of metastatic lung squmaous cancers, which were diagnosed by pathology and accepted gemcitabine or paclitaxol combined platinum as first - line chemotherapy regimens from June 2008 to May 2012. There were 31 patients in each group. Results：The objective response rate of gemcitabine platinum doublets and paclitaxel platinum doubiets were 32.3% and 35.5% （P = 0.737 ）. The median time to progression were five months（95% confidence interval was 3.2 -6.8 months） and five months（95% confi- dence interval was 3.7 -6.3 months） （P = 0.058 ）. The median overall survival were 10 months （95 % confidence in- terval was 8.9 - 11.1 months） and 12 months （95% confidence interval was 9.7 - 14.3 months） （ P = 0. 087）. Con- clusion：The clinical efficacy of gemcitabine platinum doublets and paclitaxel platinum doublets was similar in ad- vanced squamous lung cancer and there was a trend that pachtaxel platinum doublets had advantages over gemcitabie platinum doublets.

关 键 词：鳞癌 肺 晚期 铂二联 一线 

分 类 号：R734.2[医药卫生—肿瘤]